Premium
Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study
Author(s) -
Shaheen Maha Adel,
Salem Samar Abdallah M.,
Fouad Dina Adel,
ElFatah Abeer Aly Abd
Publication year - 2015
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12230
Subject(s) - medicine , mmr vaccine , measles , rubella , tuberculin , clinical efficacy , immunology , vaccination , tuberculosis , pathology
Intralesional purified protein derivative (PPD) or mumps, measles, rubella (MMR) were not previously compared regarding their efficacy or mechanism of action in treatment of warts. We aimed to compare their efficacy in treatment of multiple warts and investigate their effect on serum interleukin (IL)‐4 and IL‐12. Thirty patients with multiple warts were included (10 treated with PPD, 10 with MMR, and 10 with normal saline (control)). Injection was done every 3 weeks until clearance or maximum of three treatments. Clinical response of target and distant warts was evaluated. Serum ILs‐4 and ‐12 were assessed before and after treatment. A significantly higher rate of complete response was found in target and distant warts with PPD (60% each) and MMR (80%, 40%, respectively) compared with controls (0%), with no significant difference between both treatments. After treatment, the control group showed the lowest serum IL‐12 and IL‐4 levels compared with the MMR‐ and PPD‐treated groups with statistically significant difference in between. MMR resulted in a significantly higher serum IL‐12 than PPD. With PPD, IL‐4 was increased with statistically significant change compared with pretreat‐ment level. Intralesional PPD and MMR show comparable efficacy and safety in treatment of multiple warts. Serum ILs‐4 and‐12 increase following antigen injection.